teplizumab or placebo

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes Mellitus

Conditions

Type 1 Diabetes Mellitus

Trial Timeline

Aug 1, 2010 โ†’ Feb 1, 2011

About teplizumab or placebo

teplizumab or placebo is a phase 1 stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01189422. Target conditions include Type 1 Diabetes Mellitus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01189422Phase 1Terminated